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ABSTRACT
Perivascular cells (PC) were recently implied as regulators of metastasis and 
immune cell activity. Perivascular heterogeneity in clinical samples, and associations 
with other tumor features and outcome, remain largely unknown.
Here we report a novel method for digital quantitative analyses of vessel 
characteristics and PC, which was applied to two collections of human metastatic 
colorectal cancer (mCRC).
Initial analyses identified marker-defined subsets of PC, including cells 
expressing PDGFR-β or α-SMA or both markers. PC subsets were largely independently 
expressed in a manner unrelated to vessel density and size. Association studies 
implied specific oncogenic mutations in malignant cells as determinants of PC status. 
Semi-quantitative and digital-image-analyses-based scoring of the NORDIC-VII cohort 
identified significant associations between low expression of perivascular PDGFR-α 
and -β and shorter overall survival. Analyses of the SPCRC cohort confirmed these 
findings. Perivascular PDGFR-α and -β remained independent factors for survival in 
multivariate analyses.
Overall, our study identified host vasculature and oncogenic status as 
determinants of tumor perivascular features. Perivascular PDGFR-α and -β were 
identified as novel independent markers predicting survival in mCRC. The novel 
methodology should be suitable for similar analyses in other tumor collections.
               Research Paper
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INTRODUCTION
Pericytes surround the endothelial cells of small 
vessels and are embedded in their basement membrane. 
Through interactions with endothelial cells, pericytes are 
involved in vessel function and maturation, which includes 
reciprocal paracrine interaction between endothelial cells 
and pericytes. Pericyte function is controlled by growth 
factors including PDGFs, members of the TGFbeta family, 
sphingosine-1-phosphate-1 (S1P1) and Ang1 (reviewed in 
[1]). General interest in pericytes has increased based on 
recent studies showing that subsets of pericytes act as cell-
of-origin for fibroblast-like cells in scarring tissue, fibrosis 
and gliosis [2–6]. Most tissue analyses of pericytes rely on 
use of one or multiple marker proteins including Platelet-
derived growth factor (PDGF) α-tyrosine kinase receptors 
(PDGFR-α), PDGFR-β, α-SMA, desmin, NG2 and RGS5 
[7–10]. Although not systematically investigated, most 
data suggest that these markers are expressed in a non-
overlapping manner and might be linked to yet-to-be-defined 
functionally relevant pericyte subsets.
A series of recent studies has also highlighted potential 
important roles of perivascular cells in different aspects of 
tumor biology. Earlier studies, focusing on tumor growth 
as end-point, have demonstrated both tumor-stimulatory 
and -inhibitory effects of increased pericyte coverage, 
indicating different context-dependent and tumor type-
specific mechanisms [11–13]. These findings have recently 
been expanded by experimental studies, which have linked 
pericytes to metastasis, immune cell infiltration and efficacy 
of anti-angiogenic treatment [10, 14–16].
Together these experimental studies provide a strong 
rational for a more detailed analyses of perivascular status 
in clinical samples. Analyses of perivascular cells in clinical 
samples remain scarce, although some early studies have 
reported associations with survival [7, 10, 17]. Notably, these 
studies have been limited to the use of a single marker, thus 
failing to explore the presence of marker-defined subsets. 
Furthermore, outcome-related studies have relied on semi-
quantitative manual scoring methods with limited stringency 
and accuracy.
This study presents a detailed characterization of 
perivascular heterogeneity in human colorectal cancer 
including digital-image-analyses-based quantification. A 
series of findings are presented including novel candidate 
determinants of tumor perivascular status and previously 
un-recognized associations between marker-defined 
perivascular subsets and survival.
RESULTS
Perivascular markers show independent and 
heterogeneous expression in CRC when analyzed 
at cellular, vessel or case basis
Results of this study are based on analyses of two 
independent tumor cohorts which have been analyzed with 
four perivascular markers and evaluated with two scoring 
approaches. A summary of the data-set and scoring is 
presented in Supp. Item 1.
Initial analyses of perivascular cells in CRC aimed 
at exploring heterogeneity in marker expression at the 
cellular, vessel and case levels. These analyses focused on 
the markers PDGFR-β, α-SMA and desmin.
For high-resolution analyses of marker-expression, 
triple immuno-fluorescence staining was done with the 
endothelial cell marker CD34 and the two of perivascular 
markers: PDGFR-β and α-SMA. As shown in Figure 1A 
all three possible marker-defined perivascular cell subsets, 
i.e. PDGFR-β- and α-SMA-single positive cells and 
double-positive cells were identified by these analyses.
The next analyses focused on inter-vessel variation 
in individual tumors. These analyses identified a large 
degree of inter-vessel variation inside tumors with vessels 
of the same tumors showing e.g. high or low perivascular 
PDGFR-β expression which occurred in the absence or 
presence of α-SMA expression (Figure 1B).
Furthermore, perivascular status was compared in 
an inter-case manner. As shown at the microphotographs 
on Figure 1C (left panel) using PDGFR-β and α-SMA 
as perivascular markers, large tumor areas may be 
characterized by either low or high marker expression. 
The large degree of inter-case variations of perivascular 
α-SMA, PDGFR-β and desmin is illustrated on Figure 1C, 
right panel. This inter-case variability was also confirmed 
by semi-quantitative scoring of perivascular PDGFR-β 
and PDGFR-α (see Supp Item. 2)
Perivascular status in primary tumors is 
independent of vessel size and density but 
associated with BRAF mutation status and 
perivascular status in normal tissue
The observation of large inter-case variations in 
perivascular status prompted a set of analyses exploring 
the potential mechanism(s) causing this variability.
An analytical pipeline was developed for more 
detailed quantification of marker-defined perivascular 
cells and vessel characteristics. This digital analyses 
define vessel diameter, vessel density and produce two 
perivascular “metrics” for each perivascular marker: 
perivascular intensity (PVI) and fraction covered 
vessels (FCV) (for details see Materials and Methods, 
Supp. Methods and Supp. Items 3). For the validation 
of the digital quantification two independent observers 
performed semi-quantitative four-grade scoring of vessel 
density, vessel diameter and perivascular PDGFR-β status. 
As shown in Supp. Item 4, digital measurements show 
high concordance with visual scores.
Relationships between perivascular status and vessel 
size or vessel density were analyzed in the Nordic VII 
cohort and the SPCRC cohort. In general, perivascular 
α-SMA, PDGFR-β and desmin status was largely 
independent of both vessel density and vessel size in 
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Figure 1: A. Individual perivascular cells express different markers. The triple staining with both perivascular cell markers 
(PDGFR-β (red) or α-SMA (green)) and CD34 (blue) demonstrate presence of perivascular cells of three distinct perivascular cell types: 
PDGFR-β- and α-SMA-single positive cells and double-positive cells. B. Individual vessels are characterized by relatively 
independent perivascular expression of PDGFR-β and α-SMA. Serial sections of three vessels stained with α-SMA (blue staining, 
upper panels) or PDGFR-β (blue staining, lower panel) and CD34 (brown or red staining) showing independent perivascular expression 
of PDGFR-β and α-SMA. Note in left part an α-SMA-high / PDGFR-β-high vessel, in the middle part an α-SMA-low / PDGFR-β –high 
vessel and in right an α-SMA-high / PDGFR-β-low vessel. C. Inter-tumoral variation of perivascular marker expression. Left 
panel: Representative images of PDGFR-β and α-SMA (blue) double staining with CD34 (red or brown) showing areas of 
low or high perivascular marker expression. Note different intensity of perivascular staining (blue) in different cases. Right panel: 
Distribution of the fraction of covered vessels with PDGFR-β, α-SMA and Desmin in Nordic-VII cohort (right panel). The cases of the 
cohort are characterized by heterogeneous perivascular cell coverage defined by three markers.
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analyses correlating these features on a case basis (Figure 
2A). Similar results were obtained when correlation 
analyses were performed on individual vessels (Supp. 
Item. 5).
In the case of the Nordic VII cohort, tissue from 
normal colon was available in a number of cases. 
Interestingly, perivascular PDGFR-β and desmin but 
not α-SMA status in normal and tumor tissue showed a 
significant correlation (Figure 2B). Notably, vessel density 
and vessel size did not show this correlation (Figure 2B).
BRAF- and KRAS-mutation data from the SPCRC 
cohort allowed exploratory analyses on potential links 
between certain oncogenic features and vascular/
perivascular status. Interestingly, significant differences 
Figure 2: A. Associations between perivascular status and vessel size or vessel density. Perivascular α-SMA, PDGFR-β 
and desmin status was largely independent of both vessel density and vessel size in analyses correlating these features on a case basis. 
Spearman rank test used for statistical analysis. B. Associations of vessel size, vessel density or perivascular status between 
primary tumor and normal colon mucosa. Perivascular PDGFR-β and desmin status in normal and tumor tissue showed significant 
correlations. Notably, vessel density, vessel size and perivascular α-SMA did not show this correlation. Horizontal axes show tumor tissue 
data, vertical axes show normal tissue data. Spearman rank test used for statistical analysis. C. Associations between perivascular 
and vascular status BRAF-mutation. Statistically significant differences were detected regarding perivascular PDGFR-α, PDGFR-β 
and vessel density in tumors with or without BRAF mutation. Average values of vessel number analyzed with regard to presence of 
correlation inside one tumor/peritumoral area. p values determined by Mann–Whitney U test.
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with perivascular PDGFR-α, PDGFR-β and vessel density 
were detected between tumors with or without BRAF 
mutation (Figure 2C). No associations were detected when 
KRAS status and perivascular markers or vessel metrics 
were correlated (data not shown).
Together these analyses identify previously un-
recognized associations between perivascular features and 
host vessel status, and between perivascular features and 
tumor mutation status.
Perivascular status predicts survival in the 
nordic VII cohorts of mCRC as determined by 
two independent methods
The impact of perivascular marker expression on 
survival in mCRC has not yet been explored. To investigate 
this issue, semi-quantitative immunohistochemistry data 
for perivascular PDGFR-α and PDGFR-β (see Material 
and Methods and Supp. Item 1 for details) were collected 
and combined with clinicopathological and survival data 
from the NORDIC-VII study [18].
Low expression of either PDGFR-α or PDGFR-β was 
associated with significantly shorter overall survival (OS) 
(Figure 3A) with median OS 18.2 and 24.1 months for low 
and high PDGFR-α (p = 0.024) and 14.3 and 23.0 months 
for low and high PDGFR-β (p = 0.014), respectively. Low 
PDGFR-β expression was also associated with shorter 
progression free survival (PFS) (Supp. Item 6, upper panel, 
manual scoring).
These univariate analyses were expanded to a 
multivariate analysis, including performance status, 
alkaline phosphatase level and BRAF mutation status: three 
variables with marked prognostic importance [19–21]. 
Both perivascular markers acted as independent predictors 
of OS when tested individually in the analyses (Table 1).
To qualify these findings the next tests were 
performed using PVI and FCV metrics derived from 
the digital image analyses of the double-staining, which 
included PDGFR-β, α-SMA or desmin as perivascular 
markers and CD34 as endothelial cell marker (for details 
see Materials and Methods, Supp. Methods and Supp. 
Item 1). PDGFR-α/CD34 double staining and related 
digital analysis was not performed on the material of 
the Nordic-VII cohort due to shortage of the available 
material. Analyses of associations between perivascular 
features and clinicopathological characteristics did not 
identify any significant associations (Supp. Item 7).
Notably, low PDGFR-β PVI and FCV were 
associated with significantly shorter OS. Median OS 
was 19.7 and 28.8 months for low and high PDGFR-β 
PVI (p=0.009) and 19.7 and 31.3 months for low and 
high PDGFR-β FCV (p=0.014), respectively (Figure 
3B). Low PDGFR-β PVI and FCV were also associated 
with significantly shorter PFS, with median PFS 8.2 and 
10.9 months for low and high PDGFR-β PVI, and 8,5 
and 10,1 months for low and high PDGFR-β FCV (Supp. 
Item 6, upper panel, digital scoring). Neither α-SMA nor 
desmin showed statistically significant associations with 
OS or PFS (data not shown). Low vessel density was 
statistically significantly associated with shorter survival 
(Supp. Item 8).
Notably, both PDGFR-β-metrics acted as 
independent predictors of OS when tested individually 
in the multivariate analyses, which also included vessel 
density (Table 2).
Together these analyses thus provide novel evidence 
for an association between perivascular PDGFR-β status 
and survival in mCRC.
Perivascular status predicts survival in the 
SPCRC cohort of mCRC
Additional analyses were performed to investigate 
if the findings from the selected study population of 
NORDIC-VII could be reproduced in an independent un-
selected population of mCRC patients. For this purpose 
digital-image-analyses-derived data on perivascular 
characteristics in the SPCRC cohort were analyzed with 
regards to clinicopathological characteristics and survival.
No significant associations were detected between 
perivascular PDGFR-α and PDGFR-β marker status and 
clinical characteristics such as WHO status, number of 
metastatic sites, alkaline phosphatase levels, gender or 
tumor location (Supp. Item 9 A and B).
In agreement with the findings from the NORDIC-
VII cohort, statistically significant associations between 
low marker expression and short survival were found for 
all four PDGFR-related metrics (Figure 3C). Median OS 
for low and high PDGFR-α was 10.6 and 13.9 months (for 
both PVI and FCV with p=0.001 and 0.002, respectively). 
Median OS for low and high PDGFR-β PVI was 8.9 and 
13.8 months (p<0.001). Similar results were observed in 
PDGFR-β FCV analyses (Figure 3C). Low PDGFR-α PVI 
and FCV, were also associated with significantly shorter 
PFS, with median PFS 7.1 and 8.9 months for low and 
high PDGFR-α respectively (Supp. Item 6, lower panel).
The perivascular markers also acted as statistically 
significant independent prognostic markers, as determined 
by multivariate analyses, with HRs ranging from 1.30 
(PDGFR-α FCV) to 1.51 (PDGFR-β PVI) (Table 3).
The analyses of the SPCRC cohort thus established 
that the four perivascular metrics acted as independent 
markers of survival in a population-derived unselected 
cohort of mCRC.
Perivascular PDGFR-β is concordant in primary 
tumor and in metastasis
Based on the nature of the NORDIC VII and the 
SPCRC cohorts, the analyses above focused on survival 
of metastatic CRC following earlier surgical removal of 
the primary tumor. Notably, marker status was collected 
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Figure 3: A. Associations between perivascular expression of PDGFR-α and PDGFR-β and OS in the NORDIC-VII 
cohort (manual scoring). Low expression of both PDGFR-α and PDGFR-β is associated with statistically significantly shorter OS in 
the total study population. B. Associations between perivascular metrics PVI and FCV of PDGFR-β and OS or PFS in 
the NORDIC-VII cohort. Low PVI and FCV of PDGFR-β are associated with statistically significantly shorter OS in the total study 
population. C. Associations between perivascular metrics PVI and FCV of PDGFR-α and PDGFR-β and OS in the 
SPCRC cohort. Low PVI and FCV of both PDGFR-α and PDGFR-β are associated with statistically significantly shorter OS in the total 
study population.
Oncotarget41954www.impactjournals.com/oncotarget
Table 1: PDGFR-α and PDGFR-β as prognostic factors for overall survival in multivariate analyses in patients with 
mCRC (NORDIC-VII cohort; n=311)
Adjusted with PDGFR-α Adjusted with PDGFR-β
Variable HR (95% CI) P value HR (95% CI) P value
PDGFR-α (low vs. high) 1.44
(1.09-1.91)
0.011 - -
PDGFR-β (low vs. high) - - 1.82
(1.09-3.04)
0.023
Alkaline Phosphatase (elevated vs. normal) 2.00
(1.50-2.69)
<0.001
1.98
(1.47-2.65)
<0.001
Performance status (1 vs. 0) 1.92(1.41-2.60) <0.001
1.90
(1.40-2.57)
<0.001
Performance status (2 vs. 0) 4.02
(2.18-7.43)
<0.001
3.66
(1.99-6.73)
<0.001
BRAF (mut vs. wt) 2.94
(1.91-4.29)
<0.001
2.94
(1.09-3.04)
<0.001
Abbreviations: HR, hazard ratio; CI, confidence interval; mut, mutant; wt, wild type.
Table 2: PVI and FCV of PDGFR-β as prognostic factors for overall survival in multivariate analyses in patients 
with mCRC (NORDIC-VII cohort, n=158)
PVI FCV
variable HR (95% CI) P value HR (95% CI) P value
PDGFR-β (low vs. high) 1.78
(1.14-2.78)
0.011 1.79(1.16-2.76) 0.009
Vessel density (low vs. high) 1.80
(1.16-2.78)
0.009
1.90
(1.23-2.90)
0.004
Alkaline Phosphatase (elevated 
vs. normal)
1.85
(1.20-2.84)
0.005
1.89
(1.23-2.90)
0.004
Performance status
(1, 2 vs. 0) 
1.67
(1.07-2.61) 0.023
1.65
(1.06-2.56)
0.027
BRAF (mut vs. wt) 4.48(2.21-10.00) <0.001
4.50
(2.23-9.07)
<0.001
Abbreviations: HR, hazard ratio; CI, confidence interval; mut, mutant; wt, wild type.
from primary tumor tissue raising some concerns about 
biological significance of these findings. To address this 
issue, status of four vascular markers was compared in 
cases where information was available both from primary 
tumor and patient-matched metastasis.
As shown in Figure 4 markers showed a large 
variation in their degree of concordance. Notably only 
perivascular PDGFR-β and desmin showed a statistically 
significant concordance. Features such as vessel diameter, 
vessel density and perivascular α-SMA were not 
significantly correlated in this comparison of marker status 
in primary tumor and metastases.
Together these analyses suggest that the associations 
between perivascular PDGFR-β and survival, detected 
by analyses of primary tumor, is reflecting biological 
mechanisms likely to also be involved in the progression 
of metastatic disease.
DISCUSSION
This study identified previously un-recognized inter-
case heterogeneity of marker-defined perivascular cell 
subsets in CRC (Figure 1). According to our observation 
vessel density and perivascular PDGFR-α and -β are 
significantly associated with BRAF mutations status in 
the SPCRC cohort (Figure 2C). These findings should 
be further experimentally analyzed. Notably, BRAF-
mutations have previously been reported to be associated 
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with increased VEGF-A production [22]. Our study also 
identified strong associations between the perivascular 
PDGFR-β status of the tumor-vasculature and the host-
vasculature in histologically normal tissue (Figure 2B). 
This suggests that genetic or life-style-related host-
characteristics also contribute to inter-case perivascular 
heterogeneity. Similar findings have been made in prostate 
cancer regarding stromal PDGFR-β expression [23].
Notably, marker-defined perivascular subsets were 
independently expressed, potentially compatible with 
different regulatory mechanisms and functional differences 
between perivascular subsets, which should be further 
explored (Figure 1A-1B). Future analyses of clinical 
series should also consider other pericyte markers such as 
RGS5 and NG2. Furthermore, the analyses also showed 
that perivascular features are largely independent of vessel 
density and size (Figure 2A, Supp Item 5). This implies 
that perivascular status is governed by other factors than 
those determining vessel density and size, which should 
also be further analyzed in mechanistic studies.
Recent analyses of large datasets are emphasizing 
the contribution of stroma-derived genes to the definition 
of gene-expression-based molecular subsets of CRC [24, 
25]. Future studies on tumor collections for which gene-
expression data is available will allow further analyses 
on how the perivascular-defined groups of the present 
Figure 4: Associations of vessel size, vessel density or perivascular status between primary tumor and distant 
metastases. Perivascular PDGFR-β and desmin status in primary tumor tissue and in metastatic tissue showed significant correlations. 
Notably, vessel density, vessel size and perivascular α-SMA did not show this correlation. Horizontal axes show tumor tissue data, vertical 
axes show metastatic tissue data. Spearman rank test used for statistical analysis.
Table 3: PVI and FCV of PDGFR-α and PDGFR-β as prognostic factors for overall survival in multivariate analyses 
in patients with mCRC (SPCRC cohort)
Adjusted with PDGFR-α
n=278
Adjusted with PDGFR-β
n=307
PVI FCV PVI FCV
variable HR (95% 
CI)
P value HR (95% 
CI)
P value HR (95% 
CI)
P value HR (95% 
CI)
P value
PDGFR-α (low vs. 
high)
1.31
(0.01-1.70) 0.045
1.30
(1.00-1.68)
0.043 - - - -
PDGFR-β (low vs. 
high) - - - -
1.51
(1.18-1.94)
0.001 1.44
(1.12-1.84)
0.004
Alkaline Phosphatase 
(elevated vs. normal)
1.63
(1.26-2.10) 0.001
1.63
(1.26-2.11) <0.001
1.62
(1.26-2.08)
<0.001
1.61
(1.25-2.06)
<0.001
Performance status
(1, 2 vs. 0)
1.45
(1.10-1.91)
0.008
1.48
(1.12-1.94)
0.005
1.47
(1.13-1.92)
0.004 1.48
(1.14-1.92)
0.004
Performance status
(3, 4 vs. 0)
6.78
(4.44-
10.35)
<0.001
6.76
(4.43-
10.33)
<0.001
7.44
(5.01-
11.03)
<0.001
7.43
(5.01-
11.03)
<0.001
BRAF (mut vs. wt) 2.08
(1.46-2.94)
<0.001
2.13
(1.51-3.01)
<0.001
2.19
(1.59-3.01)
<0.001
2.21
(1.61-3.05)
<0.001
Abbreviations: HR, hazard ratio; CI, confidence interval; mut, mutant; wt, wild type.
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study are distributed among the gene-expression-based 
molecular CRC subsets.
A major finding of the present study is the 
associations between survival in mCRC and perivascular 
PDGFR status (Figure 3 and Tables 1-3). This finding is 
derived from analyses of two different mCRC cohorts, 
one including homogeneously treated trial patients and 
one unselected patients, with two independent IHC 
scoring methods. These associations remained statistically 
significant in multivariate analyses including three of 
the most important prognostic parameters in mCRC: 
performance status, alkaline phosphatase level and BRAF 
mutation status [19–21] (Tables 1-3).
All cases of NORDIC-VII and the majority of cases 
in the SPCRC received chemotherapy treatment. The study 
therefore does not allow a distinction between effects 
of perivascular markers on natural course of disease or 
response to treatment. Exploratory analyses of relationship 
of markers to PFS yielded some significant associations 
detected with PDGFR-α and PDGFR-β in the SPCRC and 
NORDIC-VII cohorts, respectively (Supp. Item. 6). No 
evidence for impact of perivascular status on cetuximab 
benefit was detected in analyses of the Nordic VII cohort 
(data not shown). Future studies are therefore warranted 
in other tumor collections in order to separately define the 
effects of perivascular cells on the natural course of the 
disease and on response to therapy.
Associations between pericyte status and survival 
have been reported in other tumor types. Analyses of 
patients with primary breast cancer noted, as in this study, 
an association between low pericyte coverage, determined 
by NG2 IHC, and poor prognosis [10]. In contrast, the 
analyses of serous ovarian cancer and renal cell cancer 
patients identified a statistically significant relationship 
between high pericyte coverage (determined by PDGFR-β 
and α-SMA respectively) and poor prognosis [17, 26].
The present study, restricted to analyses of 
clinical samples, does not address the mechanistic 
basis underlying the associations between survival 
and perivascular status. In the case of breast cancer, 
experimental studies have linked the reduced pericyte 
coverage with a hypoxic tumor state promoting an 
invasive HGF/c-met-dependent phenotype [10]. A 
more recent experimental breast cancer study linked 
low pericyte coverage to increased pro-metastatic 
Angiopoietin-2 signaling [16]. Other studies, using 
genetically modified mice, have suggested that reduced 
pericyte coverage is associated with an increased vascular 
permissiveness for intravasation [27]. Studies in mouse 
models have also suggested that the perivascular status 
will affect tumor immune surveillance [15]. Further 
correlative analyses should investigate to what extent 
these different mechanisms, identified in animal models, 
can explain the clinical associations of the present study.
Pre-clinical studies have indicated that pericyte-status 
affects survival signaling in endothelial cells and sensitivity 
to anti-angiogenic drugs, including VEGF-targeting agents 
[28–31]. Interestingly, correlative analyses of a neo-adjuvant 
breast cancer study just recently suggested that high 
perivascular coverage, as determined by perivascular ASMA 
quantification, was associated with benefit of bevacizumab 
[32]. It thus appears highly motivated to use, in future 
studies, the methods of the present study also to analyze 
impact of vascular and perivascular features on response of 
CRC to bevacizumab.
In conclusion, this study identifies novel 
independent markers associated with survival of metastatic 
CRC, highlights the relevance of perivascular cells in CRC 
tumor biology and thereby also suggests novel points for 
therapeutic interference.
MATERIALS AND METHODS
A synopsis of the materials and methods is presented 
here. Full details are provided in the Supplementary Data.
Tissue microarrays (TMAs) from the NORDIC-VII 
cohort of mCRC [18] from the open-label randomized 
investigator-initiated, multicenter phase III trial (for details 
see Supp. Methods) were used for initial perivascular 
marker analyses.
The initial analyses were performed on 318 cases from 
NORDIC-VII cohort using single staining to PDGFR-α and 
PDGFR-β. The manual scoring and semi-quantitative four-
grade system was used to evaluate perivascular expression 
of the markers (see Supp. Methods).
Digital image analyses
To improve characterization of perivascular cells, 
a set of novel integrated analytical procedures were 
developed. These include double staining with antibodies 
to endothelial cell markers and pericyte markers and 
subsequent computerized analysis of digital images 
which was used to extract two “metrics” related to the 
perivascular staining: Perivascular Intensity (PVI) and 
Fraction of Covered Vessels (FCV), (for details see Supp. 
Methods).
The extended digital-image-analyses were 
performed on a subset of the 163 cases from the NORDIC-
VII cohort (for the inclusion criteria see Supp. Methods) 
using three double staining with perivascular markers (one 
of PDGFR-β, α-SMA or desmin) and the endothelial cell 
marker CD34.
The SPCRC cohort of mCRC [33, 34], which 
represents an unselected population of all non-resectable 
histologically confirmed mCRC, was used for validation 
of findings from the NORDIC-VII cohort (Supp. 
Methods). Double staining with either of the perivascular 
markers PDGFR-α (n=323) or PDGFR-β (n=355) and 
the endothelial cell marker CD34 were made and results 
quantified by digital-image-analyses.
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Statistical analyses
All statistical tests were carried out using SPSS V20 
(SPSS Inc., Chicago, IL). p values <0.05 were considered 
statistically significant (see Supp. Methods for details).
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